Year All2024202320222021 Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 09-24-2024 Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C 09-20-2024 Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium 09-06-2024 Zevra Therapeutics to Participate at Upcoming Investor Conferences 08-29-2024 Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights 08-13-2024 Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock 08-09-2024 Zevra Therapeutics Announces Proposed Public Offering of Common Stock 08-08-2024 Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference 08-07-2024 FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C 08-02-2024 Zevra Therapeutics to Report Second Quarter 2024 Financial Results 07-30-2024
Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024 09-24-2024
Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C 09-20-2024
Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium 09-06-2024
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C 08-02-2024
